Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1581772rdf:typepubmed:Citationlld:pubmed
pubmed-article:1581772lifeskim:mentionsumls-concept:C0012655lld:lifeskim
pubmed-article:1581772lifeskim:mentionsumls-concept:C0199236lld:lifeskim
pubmed-article:1581772lifeskim:mentionsumls-concept:C0439793lld:lifeskim
pubmed-article:1581772lifeskim:mentionsumls-concept:C0151449lld:lifeskim
pubmed-article:1581772lifeskim:mentionsumls-concept:C1420806lld:lifeskim
pubmed-article:1581772lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:1581772pubmed:issue5lld:pubmed
pubmed-article:1581772pubmed:dateCreated1992-6-16lld:pubmed
pubmed-article:1581772pubmed:abstractTextA study of HLA and primary Sjögren's syndrome (1 degree SS) was performed in 40 index cases and 180 relatives all of whom were Caucasian. The association of DR3 and 1 degree SS was confirmed. In probands, DR3 associated with extraglandular manifestations of 1 degree SS and homozygosity for DR3 associated with younger onset of disease. Familial clustering of 1 degree SS was evident. Definite or probable 1 degree SS (Fox criteria) occurred with a prevalence of 4.4% in the relatives, exclusively in older female first degree relatives and was associated with DR3. The relative risk was greatest in those who expressed anti-nuclear factor, rheumatoid factor or Ro and DR3. We identified a group of young females expressing some criteria for 1 degree SS and the same immunogenetic markers. They may be at risk of full expression of 1 degree SS as they become older. Milder forms of 1 degree SS were common in older relatives but not DR3 associated. 1 degree SS in males was rare and mild irrespective of immunogenetic status. Symptoms of 1 degree SS in relatives were mild or absent. Such individuals will only be identified through a family study or a community survey.lld:pubmed
pubmed-article:1581772pubmed:languageenglld:pubmed
pubmed-article:1581772pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1581772pubmed:statusMEDLINElld:pubmed
pubmed-article:1581772pubmed:monthMaylld:pubmed
pubmed-article:1581772pubmed:issn0263-7103lld:pubmed
pubmed-article:1581772pubmed:authorpubmed-author:WalkerDDlld:pubmed
pubmed-article:1581772pubmed:authorpubmed-author:FosterHHlld:pubmed
pubmed-article:1581772pubmed:authorpubmed-author:CharlesPPlld:pubmed
pubmed-article:1581772pubmed:authorpubmed-author:KellyCClld:pubmed
pubmed-article:1581772pubmed:authorpubmed-author:GriffithsIIlld:pubmed
pubmed-article:1581772pubmed:authorpubmed-author:CavanaghGGlld:pubmed
pubmed-article:1581772pubmed:issnTypePrintlld:pubmed
pubmed-article:1581772pubmed:volume31lld:pubmed
pubmed-article:1581772pubmed:ownerNLMlld:pubmed
pubmed-article:1581772pubmed:authorsCompleteYlld:pubmed
pubmed-article:1581772pubmed:pagination309-14lld:pubmed
pubmed-article:1581772pubmed:dateRevised2007-5-11lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:meshHeadingpubmed-meshheading:1581772-...lld:pubmed
pubmed-article:1581772pubmed:year1992lld:pubmed
pubmed-article:1581772pubmed:articleTitleAssociation of DR3 with susceptibility to and severity of primary Sjögren's syndrome in a family study.lld:pubmed
pubmed-article:1581772pubmed:affiliationDepartment of Rheumatology, Royal Victoria Infirmary, Newcastle upon Tyne.lld:pubmed
pubmed-article:1581772pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1581772pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed